Clinical Trials Directory

Trials / Completed

CompletedNCT00538967

The Effect of Doxycycline on Matrix Metalloproteinase Expression and Activity in the Abdominal Aneurysm

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
60 (actual)
Sponsor
Leiden University Medical Center · Academic / Other
Sex
All
Age
Healthy volunteers
Not accepted

Summary

The matrix metalloproteinase-9 (MMP-9) is considered to play a central role in abdominal aortic aneurysm (AAA) initiation. Doxycycline has direct MMP-9 inhibiting properties in vitro, and it effectively suppresses AAA development in rodents. Observed inhibition of AAA progression, and contradictory findings in human studies evaluating the effect of doxycycline therapy on aortic wall MMP-9 suggest that the effects of doxycycline extend beyond MMP-9 inhibition, and that the effect may be dose dependent.

Detailed description

In this clinical trial, we evaluated the effect of two weeks of low (50 mg/day), medium (100 mg/day) or high dose (300 mg/day) doxycycline versus no medication in patients undergoing elective AAA repair. The effect of doxycycline treatment on MMP and cysteine proteases, and their respective inhibitors was evaluated in an integrative approach.

Conditions

Interventions

TypeNameDescription
DRUGdoxycycline2 weeks once daily

Timeline

Start date
2002-05-01
Completion
2005-08-01
First posted
2007-10-03
Last updated
2007-10-03

Locations

1 site across 1 country: Netherlands

Source: ClinicalTrials.gov record NCT00538967. Inclusion in this directory is not an endorsement.